165 Shares in Intuitive Surgical, Inc. (NASDAQ:ISRG) Acquired by Crowley Wealth Management Inc.

Crowley Wealth Management Inc. purchased a new position in Intuitive Surgical, Inc. (NASDAQ:ISRG) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 165 shares of the medical equipment provider’s stock, valued at approximately $86,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of ISRG. Atala Financial Inc acquired a new stake in shares of Intuitive Surgical in the fourth quarter worth $25,000. Berbice Capital Management LLC acquired a new stake in Intuitive Surgical during the 4th quarter worth about $26,000. BankPlus Trust Department acquired a new stake in Intuitive Surgical during the 4th quarter worth about $28,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Intuitive Surgical during the fourth quarter worth about $31,000. Finally, Decker Retirement Planning Inc. acquired a new stake in Intuitive Surgical during the fourth quarter worth about $36,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insiders Place Their Bets

In related news, VP Fredrik Widman sold 810 shares of Intuitive Surgical stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $573.78, for a total transaction of $464,761.80. Following the transaction, the vice president now owns 473 shares in the company, valued at approximately $271,397.94. This trade represents a 63.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Jamie Samath sold 269 shares of Intuitive Surgical stock in a transaction on Monday, February 10th. The stock was sold at an average price of $590.00, for a total value of $158,710.00. Following the transaction, the chief financial officer now owns 3,282 shares in the company, valued at approximately $1,936,380. This represents a 7.58 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,754 shares of company stock valued at $17,691,621 in the last ninety days. 0.90% of the stock is currently owned by corporate insiders.

Intuitive Surgical Trading Up 0.1 %

NASDAQ:ISRG opened at $492.49 on Monday. The company’s 50-day moving average price is $562.24 and its 200-day moving average price is $532.03. The company has a market cap of $175.41 billion, a P/E ratio of 76.83, a P/E/G ratio of 5.85 and a beta of 1.43. Intuitive Surgical, Inc. has a twelve month low of $364.17 and a twelve month high of $616.00.

Analysts Set New Price Targets

Several research firms recently commented on ISRG. Raymond James raised their target price on Intuitive Surgical from $560.00 to $688.00 and gave the stock an “outperform” rating in a report on Friday, January 24th. Morgan Stanley upgraded shares of Intuitive Surgical from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $522.00 to $650.00 in a research report on Monday, December 2nd. Citigroup raised their price target on shares of Intuitive Surgical from $640.00 to $711.00 and gave the company a “buy” rating in a research report on Friday, January 24th. Jefferies Financial Group raised their target price on Intuitive Surgical from $475.00 to $575.00 in a research report on Monday, January 27th. Finally, Bernstein Bank raised their target price on Intuitive Surgical from $655.00 to $700.00 and gave the company an “overweight” rating in a research report on Monday, January 27th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $611.86.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.